NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.
Topline Results of Full Study Expected Fourth Quarter 2020
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines. The program has entered stage two, which is focused on both scaling up the manufacturing of this ligand, and on the development and validation of the related affinity chromatography resin. The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines. Repligen anticipates that the final resin product will be commercially available in early 2021.
Read the original post:
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020. The presentation will reflect on Arvinas’ advances in its PROTAC® platform and introduce new pipeline programs.
Here is the original post:
Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
Schwartzman joins the newly formed Capital, Strategy, & Transactions Group Schwartzman joins the newly formed Capital, Strategy, & Transactions Group
See the rest here:
Peter A. Schwartzman Joins Radius Health, Inc.
-- Phase 2b study in healthy volunteers met primary endpoints of overall safety and induction of mucosal immunity ---- BPZE1 prevented colonization from re-vaccination/challenge in 90% of subjects with no vaccine related serious adverse events --WESTON, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) today presented positive topline Phase 2b trial results of its lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress. BPZE1, a live attenuated pertussis vaccine, met both primary endpoints of overall safety and induction of mucosal immunity.“With limited duration of immunity and the inability to significantly stop transmission, acellular vaccines have been associated with the resurgence of whooping cough,” said Cheryl Keech, M.D., Ph.D., chief medical officer and executive vice president of clinical research at ILiAD. “We need a vaccine that can effectively stop the spread of pertussis. In this study, BPZE1 demonstrated reduced nasal colonization and induction of durable mucosal immunity — two key factors necessary for the prevention of transmission and reduction of epidemic pertussis cycles.”
See original here:
ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright 4th Annual NASH Investor Conference, being held virtually on October 5, 2020.
Read more:
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
-Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer’s disease-